Alzai Health Corp. Signs Strategic U.S. Commercialization Agreement with Centauri Health Solutions to Advance AI-Driven Alzheimer's Risk Identification

About this update from Alzai Health Corp.

Alzai Health Corp. Signs Strategic U.S. Commercialization Agreement with Centauri Health Solutions to Advance AI-Driven Alzheimer's Risk IdentificationToronto, Ontario--(Newsfile Corp. - July 2, 2026) - ALZAI Health Corp. (TSXV: ALZI) ("ALZAI" or the "Company"), is pleased to announce that it has entered into a strategic teaming agreement (the "Agreement") with Centauri Health Solutions ("Centauri"), a leading U.S. healthcare technology company serving 60 million members through advanced mission-critical technology, data intelligence, and engagement solutions delivered to U.S. health plans, healthcare providers and health systems. Under the Agreement, Centauri and ALZAI will collaborate to market Ai-driven risk stratification to identify patients at high risk for early-stage undiagnosed Alzheimer's Disease. Centauri will leverage its national relationships with providers and health plans, while ALZAI contributes its proprietary AI-driven risk stratification platform and technical expertise. The collaboration accelerates U.S. launch of ALZAI's Alzheimer's risk identification technology across Medicare Advantage and other value-based care settings."This Agreement represents an important milestone in ALZAI commercialization and expansion into the U.S. healthcare market," said Hayim Raclaw, Chief Executive Officer of ALZAI Health Corp. "Centauri brings extensive relationships across the healthcare ecosystem and deep experience supporting health plans and provider organizations. Combining Centauri's market access with ALZAI's AI-powered risk identification technology expands our ability to help healthcare organizations identify individuals at elevated risk for Alzheimer's earlier in the care continuum. Early identification of at-risk individuals has become an increasingly important clinical and economic priority. More than seven million Americans are living with Alzheimer's Disease at an estimated cost of $384 billion annually in direct care, according to the Alzheimer's Association. This collaboration aligns with our vision of making proactive disease identification more accessible and scalable across healthcare systems. We believe Alzheimer's disease represents one of the most significant unmet needs in healthcare today, and this partnership positions ALZAI to participate in one of the most compelling emerging opportunities in preventive healthcare, populati...

View stock analysis, news, and events for Alzai Health Corp.